Triton agrees to acquire Atnahs Pharma

Financial details of the transaction remain undisclosed, though Triton is currently deploying capital from its €5bn buyout fund, Triton Fund V, which held a final close in January this year.

Atnah has undertaken an acquisitive international expansion strategy in recent years. It launched a Dubai office in December 2018 and acquired the remaining stakes in Danish business Pharmanovia in February 2018.

The business has come under scrutiny in the UK national media for reportedly acquiring drugs that are commonly used by the National Health Service – including antidepressants – and increasing their cost.

Company
Founded in 2013 and headquartered in Basildon, Atnahs acquires post-patent-expiry prescription medicines and develops new formulations of, or new markets for, those products. The company generated sales of £107m and an operating profit of £28m in 2018, according to publicly available documents.

People
Atnahs Pharma – Vijay Patel, Bhikhu Patel (co-founders).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Buyouts
• UK / Ireland
• Healthcare
• United Kingdom
• Triton Partners